




[< Back to results](#) | 1 of 1
[Export](#)
[Download](#)
[Print](#)
[E-mail](#)
[Save to PDF](#)
[Add to List](#)
[More... >](#)
[View at Publisher](#)
 International Journal of Medical Sciences [Open Access](#)
 Volume 16, Issue 2, 2019, Pages 450-460

Papillary thyroid cancer : Genetic alterations and molecular biomarker investigations (Review) [\(Open Access\)](#)

 Abdullah, M.I.^{a,e}, Junit, S.M.^a, Ng, K.L.^b, Jayapalan, J.J.^c, Karikalan, B.^d, Hashim, O.H.^{a,c}


^aDepartment of Molecular Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, 50603, Malaysia^bDepartment of Surgery, Faculty of Medicine, University of Malaya, Kuala Lumpur, 50603, Malaysia^cUniversity of Malaya Centre for Proteomics Research, Faculty of Medicine, University of Malaya, Kuala Lumpur, 50603, Malaysia[View additional affiliations](#) 


Abstract

[View references \(121\)](#)

Papillary thyroid cancer (PTC) is the most prevalent form of malignancy among all cancers of the thyroid. It is also one of the few cancers with a rapidly increasing incidence. PTC is usually contained within the thyroid gland and generally biologically indolent. Prognosis of the cancer is excellent, with less than 2% mortality at 5 years. However, more than 25% of patients with PTC developed a recurrence during a long term follow-up. The present article provides an updated condensed overview of PTC, which focuses mainly on the molecular alterations involved and recent biomarker investigations. © Ivyspring International Publisher.

SciVal Topic Prominence

Topic: Thyroid Neoplasms | Carcinoma, Papillary | follicular variant

Prominence percentile: 98.209 

Author keywords

[Biomarker](#)
[Diagnostics](#)
[Genetic signature](#)
[Molecular alteration](#)
[Papillary thyroid cancer](#)

Indexed keywords

 EMTREE drug terms:
 [B Raf kinase](#)
[biological marker](#)
[microRNA](#)
[protein tyrosine kinase inhibitor](#)
[proteome](#)
[radioactive iodine](#)

 EMTREE medical terms:
 [BRAF gene](#)
[cancer classification](#)
[cancer prognosis](#)
[cancer recurrence](#)
[cancer risk](#)
[carcinogenesis](#)
[chromosome rearrangement](#)
[diagnostic accuracy](#)
[echography](#)
[fine needle aspiration biopsy](#)
[gene mutation](#)
[gene rearrangement](#)
[genetic marker](#)
[human](#)
[nodular goiter](#)
[nonhuman](#)
[oncogene ras](#)
[oncogene ret](#)
[point mutation](#)
[protein expression](#)
[Review](#)
[thyroid papillary carcinoma](#)
[thyroidectomy](#)

Funding details

Funding sponsor	Funding number	Acronym
-----------------	----------------	---------

Metrics

0 Citations in Scopus

0 Field-Weighted Citation Impact



PlumX Metrics

Usage, Captures, Mentions, Social Media and Citations beyond Scopus.

Cited by 0 documents

Inform me when this document is cited in Scopus:

[Set citation alert >](#)[Set citation feed >](#)

Related documents

Etiopathogenesis of differentiated thyroid carcinomas

 Makazlieva, T. , Vaskova, O. , Majstorov, V.
 (2016) *Macedonian Journal of Medical Sciences*

Molecular characteristics of papillary thyroid carcinomas without BRAF mutation or RET/PTC rearrangement: Relationship with clinico-pathological features

 Durand, S. , Ferraro-Peyret, C. , Joufre, M.
 (2009) *Endocrine-Related Cancer*

Microarray technology to investigate genes associated with papillary thyroid carcinoma

 Zhu, X. , Yao, J. , Tian, W.
 (2015) *Molecular Medicine Reports*
[View all related documents based on references](#)[Find more related documents in Scopus based on:](#)

Funding sponsor	Funding number	Acronym
Universiti Malaya	BR002-2017	UM
Universiti Malaya	FG017-17AFR	UM

Funding text

This work was supported by the FG017-17AFR and BR002-2017 grants from the University of Malaya.

ISSN: 14491907

Source Type: Journal

Original language: English

DOI: 10.7150/ijms.29935

PubMed ID: 30911279

Document Type: Review

Publisher: Ivyspring International Publisher

References (121)

View in search results format >

All Export Print E-mail Save to PDF Create bibliography

View all 121 references

- 1 Lam, A.K.
Pathology of Endocrine Tumors Update: World Health Organization New Classification 2017-Other Thyroid Tumors (2017) *AJSP: Reviews & Reports*, 22, pp. 209-216. Cited 10 times.
-
- 2 Bychkov, A.
World Health Organization (WHO) Classification. Cited 2 times.
Accessed September 11th, 2018
<http://www.pathologyoutlines.com/topic/thyroidwho.html>
-
- 3 Maia, F.F.R., Zantut-Wittmann, D.E.
Thyroid nodule management: Clinical, ultrasound and cytopathological parameters for predicting malignancy ([Open Access](#))
(2012) *Clinics*, 67 (8), pp. 945-954. Cited 13 times.
<http://www.scielo.br/pdf/clin/v67n8/a15v67n8.pdf>
doi: 10.6061/clinics/2012(08)15

View at Publisher
-
- 4 Paricharttanakul, N.M., Saharat, K., Chokchaichamnankit, D., Punyarit, P., Srisomsap, C., Svasti, J.
Unveiling a novel biomarker panel for diagnosis and classification of well-differentiated thyroid carcinomas ([Open Access](#))
(2016) *Oncology Reports*, 35 (4), pp. 2286-2296. Cited 9 times.
<http://www.spandidos-publications.com/or/35/4/2286/download>
doi: 10.3892/or.2016.4567

View at Publisher